{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T22:34:26Z","timestamp":1789857266344,"version":"4.0.1"},"reference-count":49,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,6,13]],"date-time":"2016-06-13T00:00:00Z","timestamp":1465776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:p>This phase Ib, dose\u2010escalation study investigated the maximum tolerated dose (<jats:styled-content style=\"fixed-case\">MTD<\/jats:styled-content>), recommended phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> dose (<jats:styled-content style=\"fixed-case\">RP<\/jats:styled-content>2D), safety, pharmacokinetics (<jats:styled-content style=\"fixed-case\">PK<\/jats:styled-content>) and preliminary efficacy of the pan\u2010class I phosphoinositide 3\u2010kinase (<jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>3K) and mechanistic target of rapamycin (<jats:styled-content style=\"fixed-case\">mTOR<\/jats:styled-content>) inhibitor voxtalisib [30 or 50\u00a0mg twice daily (<jats:styled-content style=\"fixed-case\">BID<\/jats:styled-content>)], in combination with rituximab (voxtalisib+rituximab) or rituximab plus bendamustine (voxtalisib+rituximab+bendamustine), in relapsed or refractory indolent B\u2010cell non\u2010Hodgkin lymphoma (<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>), mantle cell lymphoma and chronic lymphocytic leukaemia (<jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content>). <jats:styled-content style=\"fixed-case\">MTD<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">RP<\/jats:styled-content>2D of voxtalisib were determined using a 3\u00a0+\u00a03 dose\u2010escalation design. Adverse events (<jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s), plasma <jats:styled-content style=\"fixed-case\">PK<\/jats:styled-content> and disease response were recorded. Thirty\u2010seven patients were enrolled. The <jats:styled-content style=\"fixed-case\">RP<\/jats:styled-content>2D of voxtalisib in combination with rituximab or rituximab+bendamustine was 50\u00a0mg <jats:styled-content style=\"fixed-case\">BID<\/jats:styled-content>. Four patients experienced a total of five dose\u2010limiting toxicities. The most frequent <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s were nausea (45\u00b79%), fatigue (37\u00b78%) headache (32\u00b74%) and pyrexia (32\u00b74%). The most frequent grade \u22653 <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s were neutropenia (27\u00b70%), thrombocytopenia (24\u00b73%), anaemia (16\u00b72%) and febrile neutropenia (10\u00b78%). Voxtalisib <jats:styled-content style=\"fixed-case\">PK<\/jats:styled-content> parameters were not affected by co\u2010administration with rituximab or rituximab+bendamustine. Of 35 efficacy\u2010evaluable patients, four (11\u00b74%) achieved complete response and 13 (37\u00b71%) achieved partial response. Voxtalisib, in combination with rituximab or rituximab+bendamustine, demonstrated an acceptable safety profile and encouraging anti\u2010tumour activity in relapsed or refractory B\u2010cell malignancies.<\/jats:p>","DOI":"10.1111\/bjh.14181","type":"journal-article","created":{"date-parts":[[2016,6,13]],"date-time":"2016-06-13T06:13:21Z","timestamp":1465798401000},"page":"55-65","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Phase Ib trial of the <scp>PI<\/scp>3K\/<scp>mTOR<\/scp> inhibitor voxtalisib (<scp>SAR<\/scp>245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B\u2010cell malignancies"],"prefix":"10.1111","volume":"175","author":[{"given":"Farrukh T.","family":"Awan","sequence":"first","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center Columbus OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"Gore","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Program University of Colorado Comprehensive Cancer Center Aurora CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Gao","sequence":"additional","affiliation":[{"name":"Sanofi Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Sharma","sequence":"additional","affiliation":[{"name":"Sanofi Bridgewater NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Lager","sequence":"additional","affiliation":[{"name":"Sanofi Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano J.","family":"Costa","sequence":"additional","affiliation":[{"name":"University of Alabama Birmingham AL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,6,13]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.13.113"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008416911099"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2342"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.86.86"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-535047"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3262"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-2043-3"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.1984.1984"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.525"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3641"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1022770"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.677.677"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-538546"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4204"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315226"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314583"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0226"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08123.x"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.15_suppl.8518"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24714"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-537555"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.02.010"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.03.017"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2926"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1992"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-1171"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-010-1254-8"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2403"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.974040"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.3704.3704"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1305656110"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20566"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-3215"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00256"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2253"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002003"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.2813"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20112092"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190902878471"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1042\/BST20130082"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0480"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2010.1.265"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.226"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1770-9"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2034"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3937"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14181","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14181","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.14181","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.14181","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.14181","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T13:33:40Z","timestamp":1693229620000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,13]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1111\/bjh.14181"],"URL":"https:\/\/doi.org\/10.1111\/bjh.14181","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,13]]},"assertion":[{"value":"2016-02-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-04-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-06-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}